Verily Secures $300 Million to Expand AI Strategy and Steps Out of Alphabet's Control

Verily today announced a $300 million investment round led by Series X Capital, marking its official transition from an Alphabet subsidiary to an independent corporation. Now operating under the name Verily Health Inc., the company will use the capital to accelerate its AI-native precision health platform strategy. While Alphabet remains a significant minority investor, it no longer holds a controlling stake in the health technology firm.

The funding marks a new chapter for the entity that graduated from Google X ten years ago as one of Alphabet’s earliest moonshot bets. Stephen Gillett, Chairman and CEO of Verily, emphasized that the move brings scientific rigor together with AI to deliver the next generation of healthcare. He noted that the partnership with Series X Capital and other investors will be instrumental in this transformation of the industry.

As part of the restructuring, Verily has shifted its legal status from an LLC to a corporation. This move is designed to support the roadmap for its precision health platform, which helps customers harmonize healthcare data and deploy actionable intelligence. The company’s focus remains on making healthcare more personalized, predictive, and precise through its specialized data infrastructure. Concurrent with the funding, Verily highlighted major commercial collaborations with industry leaders like Samsung and Salesforce. A partnership with Samsung’s Galaxy Watch will help life sciences customers accelerate clinical research through biomarker development. Additionally, integration with Salesforce’s Agentforce Health will power enterprise solutions to harmonize medical information across systems.

The investment round also saw participation from UCHealth and the University of Colorado Anschutz. These healthcare systems are already using the Pre platform for AI-powered research and care transformation. Dr. Richard Zane of UCHealth described the collaboration as a generational opportunity to unlock the potential of personalized care and save patient lives.

This strategic independence allows Verily to act as a neutral data broker in the highly regulated healthcare sector. By distancing itself from the direct control of a Big Tech giant, the company can more easily navigate data privacy concerns. This positioning is vital for forming deep integrations with rival technology companies and diverse medical institutions.